Gilead (GILD) and Tempus AI (TEM) expand multi-year oncology R&D collaboration

Gilead (GILD) and Tempus AI (TEM) expand multi-year oncology R&D collaboration
Gilead (GILD) and Tempus AI (TEM) expand multi-year oncology R&D collaboration

Gilead Sciences Inc. (NASDAQ:BROWN) is one of the 8 Best Quality Stocks to Buy According to Hedge Funds. Gilead Sciences Inc. (NASDAQ:BROWN) is one of the best quality stocks to buy according to hedge funds. On April 9, Tempus AI (NASDAQ:TEM) announced an expanded multi-year collaboration with Gilead Sciences to accelerate Gilead’s oncology research and development pipeline. The agreement builds on previous work in which Gilead used de-identified multimodal data from Tempus for trial design, biomarker strategies and health outcomes analysis.

Under this new company-wide mandate, Gilead gains broader access to Tempus’ AI-powered Lens platform and dedicated analytical services for multiple cancer indications. The partnership aims to use Tempus’ extensive library of real-world data to discover biological insights that can improve clinical decision-making.

By integrating Gilead’s scientific expertise with advanced data insights, the companies seek to increase the likelihood of success of new cancer therapies. Patrick Loerch, senior vice president of clinical data science at Gilead Sciences Inc. (NASDAQ:GILD), emphasized that the collaboration focuses on putting patients at the center of innovation through data-driven research. The collaboration underscores the growing role of AI and real-world evidence in modern drug development and precision medicine.

Gilead (GILD) and Tempus AI (TEM) expand multi-year oncology R&D collaboration

Copyright: dolgachov / 123RF Stock Photo

Gilead Sciences Inc. (NASDAQ:GILD) is a drug manufacturer that develops medicines for unmet medical needs. The company offers treatments for HIV-1, chronic hepatitis C, primary biliary cholangitis, chronic hepatitis B, and serious invasive fungal infections. It also offers T-cell and CAR T-cell therapies for adult patients, intravenous injections, and treatments for COVID-19.

Tempus AI Inc. (NASDAQ:TEM) is a healthcare technology company that uses artificial intelligence to advance precision medicine.

While we recognize GILD’s potential as an investment, we believe certain AI stocks offer greater growth potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that’s also benefiting significantly from Trump-era tariffs and the offshoring trend, check out our free report on best short-term AI stock.

READ NEXT: 33 stocks that should double in 3 years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

Source link